Close
Nordic 9Nordic 9

adMare BioInnovations (investor - None)

Canada admarebio.com
See something wrong or missing? Let us know
Offices:Vancouver

adMare BioInnovations is a global life sciences venture, building Canadian life sciences

Average round investment:36.5M USD
Average number per year:1.0
Distribution: 2024 (1)2022 (1)
Portfolio companies: United Kingdom EpitopeaFrance Domain Therapeutics
Mostly invests in: United Kingdom United Kingdom (1) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to adMare BioInnovations

Name Criteria
Hong Kong CR-CP Life Science Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States KB Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Rosetta Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Venrock
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
China Zhejiang NHU
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Rick Klausner
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France BOLD - Business Opportunities for L'Oréal Development
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan UTokyo IPC
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Didier Rousseau
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Kyoritsu Holdings
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top